Document is current
Any future updates will be listed below
-
Authors
Mallardo, Domenico
Simeone, Ester
Vanella, Vito
Vitale, Maria Grazia
Palla, Marco
Scarpato, Luigi
Paone, Miriam
De Cristofaro, Teresa
Borzillo, Valentina
Cortellini, Alessio
Sparano, Francesca
Pignata, Sandro
Fiore, Francesco
Caracò, Corrado
Maiolino, Piera
Petrillo, Antonella
Cavalcanti, Ernesta
Lastoria, Secondo
Muto, Paolo
Budillon, Alfredo
Warren, Sarah
Ascierto, Paolo Antonio https://orcid.org/0000-0002-8322-475X
- License Information
-
More Information
Article History
Received: 14 September 2022
Accepted: 16 September 2022
First Online: 30 September 2022
Change Date: 19 May 2023
Change Type: Update
Change Details: Missing accessibility link in the backmatter.
Declarations
:
: This study was approved by the Ethics Committee of Istituto Nazionale Tumori—IRCCS—Fondazione "G. Pascale", Naples, Italy, protocol number 17/17 oss.All patients provided their written informed consent to participate in this study.
: Consent to publication of data was given by patients.
: PAA has/had a consultant/advisory role for Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health. He also received research funding from Bristol Myers Squibb, Roche-Genentech, Pfizer, Sanofi. AC received grant consultancies from BMS, Astrazeneca, Roche and MSD. He also received speaker's fee from Astrazeneca, Novartis and Eisai. SW is employee and stockholder in NanoString Technologies. SP has/had a consultant/advisory role for Merck Sharp & Dohme, AstraZeneca, Bristol Myers Squibb, Pfizer and Roche. All other authors have declared no conflicts of interest.
